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Purpose: To compare metastasis-related mortality, local treatment failure, and globe salvage after retino-
blastoma in countries with different national income levels.
Design: International, multicenter, registry-based retrospective case series.
Participants: Two thousand one hundred ninety patients, 18 ophthalmic oncology centers, and 13 countries
on 6 continents.
Methods: Multicenter registry-based data were pooled from retinoblastoma patients enrolled between
January 2001 and December 2013. Adequate data to allow American Joint Committee on Cancer staging, eighth
edition, and analysis for the main outcome measures were available for 2085 patients. Each country was clas-
sified by national income level, as defined by the 2017 United Nations World Population Prospects, and included
high-income countries (HICs), upper middle-income countries (UMICs), and lower middle-income countries
(LMICs). Patient survival was estimated with the Kaplan-Meier method. Logistic and Cox proportional hazards
regression models were used to determine associations between national income and treatment outcomes.
Main Outcome Measures: Metastasis-related mortality and local treatment failure (defined as use of sec-
ondary enucleation or external beam radiation therapy).
Results: Most (60%) study patients resided in UMICs and LMICs. The global median age at diagnosis was
17.0 months and higher in UMICs (20.0 months) and LMICs (20.0 months) than HICs (14.0 months; P < 0.001).
Patients in UMICs and LMICs reported higher rates of disease-specific metastasis-related mortality and local
treatment failure. As compared with HICs, metastasis-related mortality was 10.3-fold higher for UMICs and 9.3-
fold higher for LMICs, and the risk for local treatment failure was 2.2-fold and 1.6-fold higher, respectively (all P <
0.001).
Conclusions: This international, multicenter, registry-based analysis of retinoblastoma management
revealed that lower national income levels were associated with significantly higher rates of metastasis-related
mortality, local treatment failure, and lower globe salvage. Ophthalmology 2021;128:740-753 ª 2020 by the
American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Supplemental material available at www.aaojournal.org.Retinoblastoma, the most frequent primary pediatric eye
cancer, has been the second most common intraocular
cancer worldwide.1e3 Patient prognosis has depended
on early diagnosis and prompt treatment.1 Advances in
chemotherapy and local treatment have resulted in
improved globe salvage and reductions in disease-specific740 ª 2020 by the American Academy of Ophthalmology
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ment, international outreach, and cooperative research are
crucial.2,3,5e15
Despite new retinoblastoma treatment strategies, ever-
widening disparities persist with respect to access to sub-
specialty care, globe salvage, and mortality.3,13,16e21 Forvier Inc.
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Tomar et al  Global Retinoblastoma Treatment Outcomesexample, retinoblastoma patients from high-income coun-
tries (HICs) in North America and Europe have a 3% to 5%
risk of metastasis-related mortality compared with 40% and
70% in resource-poor countries in Asia and Africa,
respectively.22e30 Mortality rates have been so low in HICs
that the focus of ophthalmic oncology care has shifted from
metastasis to globe salvage, visual rehabilitation, and quality
of life.4 This is not the case for low-resource countries,
where children with retinoblastoma have been more likely to
lose their eye and die of metastatic disease.2,31,32
Low-resource countries suffer from a lack of retinoblas-
toma awareness, trained ophthalmic oncologists, patholo-
gists, and genetic services. This has resulted in diagnostic
delays, leading to loss of both eyes and life. Although so-
cioeconomic and cultural factors remain a challenge,
epidemiologic and research publications from low- and
middle-income countries have been scarce.33 In addition,
the lack of a universally applied retinoblastoma
classification system has hampered communication and
made published results harder to compare and compile for
meta-analysis.34 A 2017 publication on global
retinoblastoma based on national income group showed
that children from lower- and middle-income countries
sought treatment at an older age with more advanced dis-
ease.3 However, the outcomes of metastasis-free survival
and globe salvage were not presented. Herein, we used the
American Joint Committee on CancerdOphthalmic
Oncology Task Force’s (AJCC-OOTF) multicenter, inter-
national retinoblastoma registry database to investigate the
association between treatment outcomes and national in-
come level.Methods
This study was performed on data derived from a retrospective
registry created by 18 retinoblastoma centers from 13 countries
on 6 continents. Ophthalmic oncologists from subspecialty
centers volunteered to participate; therefore, no centers were
excluded or selected with bias toward geographic location or
national income. Data from retinoblastoma patients diagnosed
from January 5, 2001, through December 31, 2013, were
collected and entered into a secure online database. Medical
record reviews were performed by all participating centers after
obtaining internal institutional review board approval. The
Princess Margaret Cancer Centre Internal Review Board (IRB)
provided study-specific application materials to each and every
participating center to be amended and approved by their local
IRB and Ethics Committee. This study adhered to the tenets of
the Declaration of Helsinki and the Health Insurance Portability
and Accountability Act of 1996.
The Registry
The internet-based, retrospective registry was created to evaluate
the staging system for retinoblastoma in the eighth edition of the
American Joint Committee on Cancer (AJCC) Cancer Staging
Manual.35 By consensus, select retinoblastoma AJCC-OOTF
committee members (primarily ophthalmic oncologists and pa-
thologists) developed epidemiologic, clinical, and pathologic data
fields. The scope of the present study was limited to assessing the
risk of metastasis-related mortality, local treatment success, andDownloaded for Anonymous User (n/a) at University of Helsi
2021. For personal use only. No other uses without permissiglobe salvage based on the national income of the participating
countries.
Internet Database and Security
International standards were ensured for secure data storage, pa-
tient privacy protection, and statistical analysis. The security
measures included the lack of personal patient identifiers, secure
sockets layer encryption, protection against structured query lan-
guage injection, variable and session management, record locking,
and trail auditing (e.g., failed login attempts and webpage
accessing). The online survey could be accessed only by the user
accounts issued by the coordinating Princess Margaret Cancer
Centre, and unique login passwords were provided after Princess
Margaret Cancer Centre had received local ethics approval docu-
mentation. The centers could access only records submitted from
their site. Princess Margaret Cancer Centre determined, and all
centers agreed, that individual patient consent was not required
because no patient identifiers were collected in this retrospective
study. All data were de-identified at the local center, where an
alphanumeric study identifier was generated for each patient. De-
identified data were entered into the AJCC-OOTF Retinoblas-
toma Registry.
Tumor Extent, Node, Metastasis, and Heritable
Trait Retinoblastoma Staging
The primary tumor extent, node status, metastasis status, and
heritable trait status were defined in accordance with the eighth
edition of the AJCC Cancer Staging Manual on retinoblastoma
(Table S1, available at www.aaojournal.org).35 We preferred AJCC
retinoblastoma classification because it is a comprehensive
classification that predicts both metastasis and globe salvage5,6;
accounts for both intraocular and extraocular retinoblastoma
extent; has been updated periodically with the latest significant
medical evidence; holistically includes tumor, node, metastasis,
and heritable trait; and has been adopted by the Union for
International Cancer Control.
Definitions
The country classification by national income level, obtained
from the 2017 World Population Prospects (United Nations,
Department of Economic and Social Affairs), segregates
participating centers into high-income countries (HICs), upper
middle-income countries (UMICs), and lower middle-income
countries (LMICs).36 No centers from lower-income countries
contributed to the AJCC-OOTF Retinoblastoma Registry. All
centers used their standard diagnostic and therapeutic methods.
Data collected included: date of diagnosis (month and year), age
at diagnosis (months), laterality (unilateral, bilateral), and the eye
involved (right or left). The clinical information included size
and location of the intraocular tumor, presence of glaucoma, and
iris neovascularization. Also noted was the type and location of
seeds (subretinal, vitreal, anterior chamber, or a combination
thereof). For bilateral retinoblastoma (by AJCC convention), the
worse-eye tumor category was attributed to the overall clinical
tumor (cT) and pathologic tumor (pT) category for survival
analysis. According to AJCC retinoblastoma staging, we classi-
fied H based on bilateral disease, family history of retinoblas-
toma, and presence of trilateral retinoblastoma, as well as the
presence of pathogenic retinoblastoma variant on genetic
testing.37
Treatment details were noted as follows. First, primary
enucleation was defined as removal of treatment-naïve retinoblas-
toma eyes. Second, secondary enucleation referred to removal of741
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Table 1. Geographic Characteristics at Presentation of 2085 Retinoblastoma Patients




North America 973 (34.1)
South America 75 (2.6)
Europe 352 (12.3)
Australia 55 (2)
Participant centers (no. of patients, % of total patients)
High income
1. St. Jude Children’s Research Hospital, Memphis (244 [11.7%])
2. Children’s Hospital Los Angeles (213 [10.2%])
3. SickKids Hospital, Toronto (163 [7.8%])
4. Helsinki University Hospital, Helsinki (62 [3.0%])
5. Hong Kong Eye Hospital, Hong Kong (48 [2.3%])
6. The Sydney Children’s Hospitals Network, Sydney (44 [2.1%)
7. KK Women’s and Children’s Hospital, Singapore (34 [1.6%])
8. Hospital Sant Joan de Deu Barcelona, Barcelona (10 [0.5%])
9. The New York Eye Cancer Center (16 [0.8%])
834 (40.0) 1171 (41.0)
Upper middle income
1. Beijing Tongren Hospital, Beijing (631 [30.3%])
2. S. Fyodorov Eye Microsurgery Federal State Institute, Moscow (78 [3.7%])
3. Hospital Infantil de Mexico Federico Gomez, Mexico City (57 [2.7%])
4. Hospital de Pediatria Garrahan, Buenos Aires (77 [3.7%])
5. N. N. Blokhin Cancer Research Center, Moscow (69 [3.3%])
912 (43.7) 1185 (41.5)
Lower middle income
1. Sankara Nethralaya Eye Hospital, Chennai (128 [6.1%])
2. King Hussein Cancer Center, Amman (112 [5.4%])
3. Narayana Nethralaya Eye Hospital, Bengaluru, India (63 [3.0%])
4. University of Ghana Medical School, Accra, Ghana (36 [1.7%])
339 (16.3) 498 (17.5)
Total 2085 2854
Ranked according to United Nations, Department of Economic and Social Affairs World Population Prospects List.37
Ophthalmology Volume 128, Number 5, May 2021an eye after an attempt at eye salvage, regardless of the reason for
enucleation (e.g., significant residual disease, recurrent tumor).
Eyes with substantial residual or recurrent disease after chemo-
therapy and focal consolidation were typically treated with further
focal laser therapy, cryotherapy, plaque brachytherapy, intra-
arterial chemotherapy, external beam radiotherapy (EBRT; not
considered as initial treatment for retinoblastoma in the present
time), and if necessary, enucleation. Third, local treatment failure
after conservative treatment was defined as the need for EBRT or
secondary enucleation.
Information regarding the survival outcome included occur-
rence of metastasis, date of detection of metastasis, the sites of
metastases, and the final patient outcome (alive without metastasis,
alive with metastasis, died with metastasis, died because of second
malignant neoplasm, death related to other causes, or lost to
follow-up). Date of last follow-up and the duration of follow-up
were noted. All patients with central nervous system metastasis
and those lost to follow-up were considered deceased and thus
included in the metastasis-related mortality analysis. Patients
whose treatment was discontinued by request of their guardians or
who were lost to follow-up without completing treatment were
recorded as having died of the disease and were included in
metastasis-related mortality. All other deaths not related to
metastasis were censored.
Patients were excluded if key variables, such as demographic
data, clinical variables essential for retinoblastoma classification742
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treatment), and outcome (globe salvage, primary or secondary
enucleation, metastatic disease, survival) were missing or
inconsistent.
Statistical Analysis
Continuous variables were described using the median, range,
and interquartile range (IQR), and categorical variables were
described using frequencies and proportions. Kaplan-Meier plots,
the log-rank test for trend, and logistic and Cox proportional
hazards regression models were implemented to test if national
income level was related independently to metastasis-related
mortality and local treatment failure. Cumulative proportion of
surviving and of local failure-free globe salvage estimates at
different intervals were tabulated using SPSS software version
23.0 (IBM, Armonk, NY) to generate Kaplan-Meier plots and
perform other statistical analyses. Statistical significance was set
at P < 0.05.Results
A total of 2190 patients were enrolled from 18 ocular oncology
centers around the world. Records with data sufficient for this
study were available for 2085 patients (95.2%).nki from ClinicalKey.com by Elsevier on December 22, 
on. Copyright ©2021. Elsevier Inc. All rights reserved.
Table 2. Clinical Characteristics at Presentation of 2085 Retinoblastoma Patients by National Income Group, Logistic Regression
Analysis, and Classification of Retinoblastoma Eyes
A. Clinical Characteristics at Presentation
Parameter
National Income Level, No. of Patients (% within the National Income Level) or [% within the Evaluated Parameter]
Total, No. (%)High Income Upper Middle Income Lower Middle Income
All patients 834 [40.0] 912 [43.7] 339 [16.3] 2085 (100)
Age at diagnosis (mos),
median (IQR)
All patients 14.0 (6.0e26.0) 20.0 (9.3e30.0) 20.0 (10.0e33.0) 17.0
(8.0e29.0)
Unilateral RB 21.0 (10.0e32.0) 24.0 (14.0e33.0) 24.0 (11.0e38.0) 23.0
(12.0e34.0)
Bilateral RB 6.0 (2.0e13.0) 10.0 (4.0e18.0) 12.5 (7.0e23.8) 9.0 (4.0e17.0)
Laterality at diagnosis
Unilateral 521 (62.6) 639 (69.8) 211 (62.5) 1371 [65.2]
Bilateral 313 (37.4) 273 (30.2) 128 (37.5) 714 [34.8]
Clinical primary
tumor
cT1 144 (17.3) 55 (6.0) 27 (8.0) 226 [10.8]
cT1a 38 (4.6) 11 (1.2) 10 (2.9) 59 [2.8]
cT1b 106 (12.7) 44 (4.8) 17 (5.1) 167 [8.0]
cT2 427 (51.2) 418 (45.8) 165 (48.7) 1010 [48.3]
cT2a 122 (14.6) 38 (4.2) 36 (10.6) 196 [9.4]
cT2b 305 (36.6) 380 (41.7) 129 (38.1) 814 [39.0]
cT3 262 (31.4) 433 (47.5) 136 (40.1) 831 [39.9]
cT3a 9 (1.1) 10 (1.1) 3 (0.9) 22 [1.1]
cT3b 84 (10.1) 62 (6.8) 20 (5.9) 166 [8.0]
cT3c 82 (9.8) 229 (25.1) 78 (23) 389 [18.7]
cT3d 61 (7.3) 112 (12.3) 30 (8.8) 203 [9.7]
cT3e 26 (3.1) 20 (2.2) 5 (1.5) 51 [2.4]
cT4 1 (0.1) 6 (0.7) 11 (3.2) 18 [0.9]
Regional lymph node
NX 374 (44.9) 785 (85.1) 199 (58.7) 1358 [65.1]
N0 458 (54.9) 123 (14.6) 131 (38.6) 712 [34.1]
N1 2 (0.2) 4 (0.4) 9 (2.7) 15 [0.7]
Distant metastasis
cMX 375 (45.0) 787 (86.3) 216 (63.7) 1378 [66.1]
cM0 454 (54.4) 118 (12.9) 110 (32.4) 682 [32.7]
cM1a 2 (0.2) 1 (0.1) 10 (2.9) 13 [0.6]
cM1b 3 (0.4) 6 (0.7) 3 (0.9) 12 [0.6]
Hereditary trait
H0 516 (61.9) 633 (69.3) 211 (62.2) 1360 [65.2]
H1 318 (38.1) 279 (30.6) 128 (37.8) 725 [34.8]
Pathological
primary tumor
pT1 218 (41.1) 168 (28.8) 105 (45.3) 491 [36.5]
pT2 189 (35.7) 228 (39.0) 46 (19.8) 463 [34.4]
pT3 111 (20.9%) 142 (24.3) 66 (28.4) 319 [23.7]
pT4 12 (2.3) 46 (7.9) 15 (6.5%) 73 [5.4]
B. Logistic Regression Analysis: Predictors of Advanced Disease at Presentation*,y
Variable B (Standard Error) P Value Odds Ratio (95% Confidence Interval)
Income level
HIC 1.0
LMIC þ UMIC 0.487 (0.095) <0.001 1.6 (1.4e2.0)
Age (mos)
<8.0 1.0
8.0e17.0 0.321 (0.134) 0.017 1.4 (1.1e1.8)
17.0e29.0 0.919 (0.129) <0.001 2.5 (2.0e3.2)
>29.0 0.885 (0.130) <0.001 2.4 (1.9e3.1)
Constant e1.214 (0.109) <0.001 0.3
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C. Classification of Retinoblastoma Eyes by National Income Group
Tumor Category
No. of Eyes (% of Total Eyes in Income Group)
High-Income Country Upper Middle-Income Country Lower Middle-Income Country
cT1
cT1a 154 (13.2) 56 (4.7) 20 (4.0)
cT1b 211 (18.0) 162 (13.7) 93 (18.7)
cT2
cT2a 93 (7.9) 66 (5.6) 121 (24.3)
cT2b 445 (38.0) 493 (41.6) 116 (23.3)
cT3 267 (22.8) 400 (33.8) 135 (27.1)
cT4 1 (0.1) 8 (0.7) 13 (2.6)
D. Classification of Retinoblastoma Eyes with Local Treatment Outcomes by National Income Group
Tumor Category Treatment Outcomes
No. of Eyes (% of Total Eyes)
High-Income Country Upper Middle-Income Country Lower Middle-Income Country
cT1
cT1a Primary enucleation 18/154 (11.7) 3/56 (5.4) 2/20 (10)
Globe salvage 134/154 (87) 49/56 (87.5) 18/20 (90)
Secondary enucleation 2/154 (1.3) 4/56 (7.1) 0/20 (0)
cT1b Primary enucleation 6/211 (2.8) 8/162 (4.9) 0/93 (0)
Globe salvage 190/211 (90) 143/162 (88.3) 90/93 (96.8)
Secondary enucleation 15/211 (7.1) 11/162 (6.8) 3/93 (3.2)
cT2
cT2a Primary enucleation 52/93 (55.9) 23/66 (34.8) 44/121 (36.4)
Globe salvage 31/93 (33.3) 31/66 (47) 54/121 (44.6)
Secondary enucleation 10/93 (10.8) 12/66 (18.2) 23/121 (19)
cT2b Primary enucleation 222/445 (49.9) 154/493 (31.2) 54/116 (46.6)
Globe salvage 159/445 (35.5) 236/493 (47.9) 33/116 (28.4)
Secondary enucleation 64/445 (14.4) 103/493 (20.9) 29/116 (25)
cT3 Primary enucleation 217/267 (81.3) 270/400 (67.5) 100/135 (74.1)
Globe salvage 20/267 (7.5) 62/400 (15.5) 18/135 (13.3)
Secondary enucleation 30/267 (11.2) 68/400 (17) 17/135 (12.6)
HIC ¼ high-income country; IQR ¼ interquartile range; LMIC ¼ lower middle-income country; UMIC ¼ upper middle-income country.
*The logistic regression model was statistically significant (chi-square (4) ¼ 111.658; P < 0.001). The model explained 7.0% (Nagelkerke R2) of the
variance and correctly classified 62.1% of cases. Area under the receiver operating characteristic curve was 0.631 (95% confidence interval, 0.607e0.655; P
< 0.001).
yAdvanced disease is defined as cT3 and cT4.
Table 2. (Continued.)
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Nearly half of the patients were from Asia (1016 [48.7%]), fol-
lowed by North America (694 [33.2%]), Europe (218 [10.5%]),
South America (77 [3.7%]), Australia (44 [2.1%]), and Africa (36
[1.7%]). Based on national income, 834 patients (40%) came from
an HIC, 912 patients (43.7%) came from a UMIC, and 339 patients
(16.3%) from an LMIC (Table 1).
Patient Features
Median age at diagnosis was 17.0 months (mean, 21.6 months;
standard deviation [SD], 20.9 months; IQR, 8e29 months; range, 1
monthe30.4 years; Table 2A). Median age at diagnosis increased
as national income level decreased (P < 0.001) at 14.0 months for
HICs (mean, 19.3 years; SD, 19.7 years; range, 1 monthe30.4
years; IQR, 6.0e26.0 years), 20.0 months for UMICs (mean,
22.4 years; SD, 18.7 years; range, 1 monthe13.6 years; IQR,
9.3e30.0 years), and 20.0 months for LMICs (mean, 24.9 years;
SD, 27.5 years; range, 10e32 years; IQR, 10.0e33.0 years).
Bilateral retinoblastoma at diagnosis was seen in 714 of 2085
patients (34.8%; 313 patients [37.4%], 273 patients [30.2%], and
128 patients [37.5%] from HICs, UMICs, and LMICs,744
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On logistic regression (Table 2B), lower national income level
and older age at presentation were found to be both independent
and significant predictive factors (P < 0.001) for advanced
disease (cT3 and cT4).
American Joint Committee on Cancer
Classification
The clinical tumor categories (cT) for all 2085 patients were: cT1a
in 59 patients (2.8%), cT1b in 167 patients (8.0%), cT2a in 196
patients (9.4%), cT2b in 814 patients (39.0%), cT3 in 831 patients
(39.9%), and cT4 in 18 patients (0.9%); Table 2A. Lymph node
involvement at presentation was seen in 15 patients: 2 patients
(0.2%) in HICs, 4 patients (0.4%) in UMICs, and 9 patients
(2.7%) in LMICs. Synchronous metastatic disease at the time of
diagnosis of the primary tumor was seen in 25 patients: 5
patients (0.6%) in HICs, 7 patients (0.8%) in UMICs, and 13
patients (3.9%) in LMICs. Heritable trait, diagnosed in 725
patients, was unrelated to national income level: 318 patients
(38.1%) in HICs, 279 patients (30.6%) in UMICs, and 128
patients (37.8%) in LMICs (Table 2A).nki from ClinicalKey.com by Elsevier on December 22, 
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Figure 1. Kaplan-Meier curves showing cumulative survival estimates for all retinoblastoma patients by national income groups. HIC ¼ high-income
country; LMIC ¼ lower middle-income country; UMIC ¼ upper middle-income country.
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Of 2085 patients, 109 (5.2%; 95% confidence interval [CI], 4.3%e
6.3%) died of metastatic disease. The other causes of death, not
included in survival analysis, were chemotherapy-related adverse
events in 4 patients (0.2%), trilateral retinoblastoma in 1 patient
(0.1%), and nonedisease-related causes in 3 patients (0.2%). The
median time from presentation to development of metastasis
(known for 92 patients) was 9.5 months (mean, 13.7 months; SD,
13.6 months; IQR, 4.0e19.8 months; range, 0 monthse13.9
years). The risk of metastasis was associated strongly with lower
national income group: 1.0% (8/826; 95% CI, 0.4%e1.9%)
demonstrated metastases in an HIC, 9.0% (75/837; 95% CI, 4.2%e
19.0%) demonstrated metastases in a UMIC, and 8.3% (26/313;
95% CI, 5.5%e11.9%) demonstrated metastases in an LMIC.
The 5-year Kaplan-Meier cumulative survival estimates by
national income were 99% for HICs, 89% (95% CI, 88%e90%)
for UMICs, and 90% (95% CI, 88%e92%) for LMICs,
respectively (Fig 1; Figs S1eS3, available at
www.aaojournal.org). Compared with HIC patients, the UMIC
and LMIC patients showed an increased risk of metastasis-
related mortality and shorter survival (P < 0.001, log-rank
test for trend; Table 3A; Table S2, available at
www.aaojournal.org). Pairwise comparison showed a
significant difference between HICs and UMICs and LMICs
(P < 0.001 for each), whereas no significant difference was
found between UMICs and LMICs (P ¼ 0.57). Cox
proportional hazards regression estimates showed that patients
in UMICs (hazard ratio [HR], 10.3; 95% CI, 5.0e21.4; P <
0.001) and those in LMICs (HR, 9.3; 95% CI, 4.2e20.5; P <Downloaded for Anonymous User (n/a) at University of Helsi
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tality compared with those in HICs (Table 4A). Multivariate
analysis revealed a higher risk of metastatic mortality with
advanced age at presentation: age of 17.0 to 29.0 months
(HR, 1.9; 95% CI, 1.0e3.3; P ¼ 0.030) and older than 29.0
months (HR, 2.3; 95% CI, 1.3e4.1; P ¼ 0.006) compared
with age at presentation younger than 8.0 months as well as
positive heritable trait status (HR, 1.6; 95% CI, 1.0e2.5; P ¼
0.027) compared with unknown or absence of heritable trait,
Hx or H0.
Of the 1353 patients who underwent primary or secondary
enucleation, 69 (5.1%; 95% CI 4.0%e6.4%) died of metastatic
disease. Histopathologic analysis was undertaken, and a pT cate-
gory was assigned for all eyes (Table 3; Table S3, available at
www.aaojournal.org). Among these, 1.3% (7/523; 95% CI,
0.5%e2.7%) demonstrated metastasis in an HIC, 8.8% (47/537;
95% CI, 6.5%e11.5%) did so in a UMIC, and 6.9% (15/217;
95% CI, 3.9%e11.1%) did so in an LMIC.
The 5-year Kaplan-Meier cumulative survival estimates
(enucleated patients) by national income were 99% (95% CI,
98%e100%) for HICs, 90% (95% CI, 89%e91%) for UMICs,
and 92% (95% CI, 90%e94%) for LMICs, respectively (Fig 2;
Figs S4eS6, available at www.aaojournal.org). Compared with
HIC patients, UMIC and LMIC patients showed an increased
risk of metastasis-related mortality and shorter survival (P <
0.001, log-rank test for trend; Table 3B; Table S3, available at
www.aaojournal.org). Pairwise comparison showed significant
differences between HICs compared with UMICs and LMICs
(P < 0.001 for each), whereas no significant difference was
found between UMICs and LMICs (P ¼ 0.37). Cox
proportional hazards regression analysis showed that745
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Table 3. Kaplan-Meier Analyses
A. Kaplan-Meier Cumulative Proportion of Surviving Patients According to National Income Group
Variable
Kaplan-Meier Estimate, % (95% Confidence Interval)
1 Year 5 Years 10 Years
All patients (N ¼ 2085) 95 (94-96) 94 (93-95) 93 (92-94)
HIC (n ¼ 834) 99 (98-100) 99 (98-100) 99 (98-100)
UMIC (n ¼ 912) 92 (91-93) 89 (88-90) 89 (88-90)
LMIC (n ¼ 339) 93 (91-95) 90 (88-92) 90 (88-92)
Overall comparison, P < 0.001
High-Income Country Upper Middle-Income Country
HIC
UMIC P < 0.001
LMIC P < 0.001 P ¼ 0.57
B. Kaplan-Meier Cumulative Proportion of Surviving Patients in All Enucleated Retinoblastoma Patients According to National Income Group
Variable
Kaplan-Meier Estimate, % (95% Confidence Interval)
1 Year 5 Years 10 Years
All patients (n ¼ 2085) 95 (94-96) 94 (93-95) 93 (92-94)
HIC (n ¼ 834) 99 (98-100) 99 (98-100) 99 (98-100)
UMIC (n ¼ 912) 93 (92-94) 90 (89-91) 90 (88-92)
LMIC (n ¼ 339) 94 (92-96) 92 (90-94) 92 (90-94)
Overall comparison, P < 0.001
High-Income Country Upper Middle-Income Country
HIC
UMIC P < 0.001
LMIC P < 0.001 P ¼ 0.37
C. Kaplan-Meier Cumulative Proportion of Avoiding Local Treatment Failure According to National Income Group
Classification
Kaplan-Meier Estimate, % (95% Confidence Interval)
1 Year 2 Years 5 Years 10 Years
All eyes (n ¼ 1574) 78 (77e79) 75 (74-76) 68 (67-69) 42 (38-46)
HIC (n ¼ 633) 84 (83e85) 83 (81-85) 77 (75-79) 48 (43-53)
UMIC (n ¼ 682) 72 (70e74) 67 (65-69) 54 (51-57) 33 (27-39)
LMIC (n ¼ 259) 75 (72e78) 72 (69-75) 69 (66-72) 61 (57-65)
Overall comparison, P <0.001
HIC UMIC
HIC
UMIC P < 0.001
LMIC P ¼ 0.002 P ¼ 0.15
HIC ¼ high-income country; LMIC ¼ lower middle-income country; UMIC ¼ upper middle-income country.
Ophthalmology Volume 128, Number 5, May 2021enucleated patients in UMICs (HR, 6.9; 95% CI, 3.1e15.3; P <
0.001) and LMICs (HR, 5.4; 95% CI, 2.2e13.2; P < 0.001)
showed a greater risk of metastasis-related death compared
with those in HICs (Table 4B). Multivariate analysis revealed a
higher risk of metastasis-related mortality in enucleated patients
with advanced age at presentation of more than 29.0 months
(HR, 2.4; 95% CI, 1.0e5.6; P ¼ 0.044) compared with those
younger than 8.0 months, but not with those 17 to 29 months of
age (P ¼ 0.067) and with positive heritable trait status (P ¼
0.373).
Local Treatment Outcomes
Of the 2854 eyes, primary enucleation was performed in 1179 and
2D)(41.3%), 1675 underwent an attempt at globe salvage, and local746
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ation became necessary in 400 eyes (14.0%; Table 2C and 2DCumulative Proportion of Avoiding Local
Treatment Failure by National Income
Of 1675 eyes not primarily enucleated, 1574 showed complete data
for globe salvage analysis and 434 (27.6%) were treated by EBRT
(90 eyes) or secondary enucleation (334 eyes) for retinoblastoma
control. Analysis by national income revealed that globe salvage
failed in 25.2% (110 were enucleated and 50 needed EBRT of 633)
in HICs, 29.8% (172 were enucleated and 31 needed EBRT of 682)
in UMICs, and 27.4% (62 were enucleated and 9 needed EBRT of
259) in LMICs. The 5-year Kaplan-Meier cumulative proportion ofnki from ClinicalKey.com by Elsevier on December 22, 
on. Copyright ©2021. Elsevier Inc. All rights reserved.
Table 4. Cox Proportional Hazards Regression
Variable No. of Patients in Category (%) Reference Wald Chi-Square
Hazard Ratio
(95% Confidence Interval) P Value
A. Cox proportional hazards regression model in all retinoblastoma patients for association of national income level with metastatic mortality
Univariate analysis (n ¼ 2085)
UMIC n ¼ 912 HIC 39.21 10.3 (5.0e21.4) <0.001
LMIC n ¼ 339 HIC 30.38 9.3 (4.2e20.5) <0.001
Multivariate analysis (n ¼ 2085)
UMIC n ¼ 912 HIC 37.4 9.8 (4.7e20.4) <0.001
LMIC n ¼ 339 HIC 27.8 8.5 (3.8e18.8) <0.001
Age (mos)
8.0e17.0 n ¼ 480 Age < 8.0 mos 0.04 0.9 (0.5e1.8) 0.839
17.0e29.0 n ¼ 532 Age < 8.0 mos 4.7 1.9 (1.0e3.3) 0.030
>29.0 n ¼ 504 Age < 8.0 mos 7.5 2.3 (1.3e4.1) 0.006
H1 n ¼ 725 H0 4.8 1.6 (1.0e2.5) 0.027
B. Cox proportional hazards regression model in all enucleated retinoblastoma patients for association of national income level with metastatic mortality
Univariate analysis (n ¼ 1353)
UMIC n ¼ 584 HIC 22.66 6.9 (3.1e15.3) <0.001
LMIC n ¼ 232 HIC 13.45 5.4 (2.2e13.2) <0.001
Multivariate analysis n ¼ 2085
UMIC n ¼ 584 HIC 21.7 6.6 (3.0e14.7) <0.001
LMIC n ¼ 232 HIC 12.4 5.1 (2.1e12.5) <0.001
Age (mos)
8.0e17.0 n ¼ 280 Age < 8.0 mos 0.2 1.2 (0.5e3.2) 0.655
17.0e29.0 n ¼ 413 Age < 8.0 mos 3.4 2.2 (1.0e4.9) 0.067
>29.0 n ¼ 387 Age < 8.0 mos 4.1 2.4 (1.0e5.6) 0.044
H1 n ¼ 383 H0 0.8 1.3 (0.7e2.3) 0.373
C. Cox proportional hazards regression model in retinoblastoma eyes for association of national income level with local treatment failure
Univariate analysis n ¼ 1353
UMIC n ¼ 682 HIC 48.07 2.2 (1.7e2.7) <0.001
LMIC n ¼ 259 HIC 9.61 1.6 (1.2e2.1) <0.001
Multivariate analysis (n ¼ 2085)
UMIC n ¼ 682 HIC 19.0 1.7 (1.3e2.1) <0.001
LMIC n ¼ 259 HIC 3.1 1.3 (1.0e1.7) 0.081
Age (mos)
8.0e17.0 n ¼ 413 Age < 8.0 mos 0.01 1.0 (0.8e1.2) 0.904
17.0e29.0 n ¼ 273 Age < 8.0 mos 31.1 2.1 (1.6e2.6) <0.001
>29.0 n ¼ 180 Age < 8.0 mos 19.6 2.0 (1.5e2.6) <0.001
Unilateral n ¼ 425 Bilateral 47.3 2.1 (1.7e2.6) <0.001
HIC ¼ high-income country; LMIC ¼ lower middle-income country; UMIC ¼ upper middle-income country.
Tomar et al  Global Retinoblastoma Treatment Outcomeseyes avoiding local treatment failure was 77% (95% CI, 75%e
79%) for HICs, 54% (95% CI, 51%e57%) for UMICs, and 69%
(95% CI, 66%e72%) for LMICs (Fig 3; Figs S6eS9, available at
www.aaojournal.org). In comparison with eye in HICs, eyes in
both UMICs and LMICs showed an increased risk of local
treatment failure and less frequent globe salvage (P < 0.001,
log-rank test for trend; Table 3C; Table S4, available at
www.aaojournal.org). Pairwise comparison revealed a significant
difference in local failure between HICs as compared with
UMICs and LMICs (P < 0.001 for each). No significant
difference existed between UMICs and LMICs (P ¼ 0.15). Cox
proportional hazards regression analysis showed that patients in a
UMIC (HR, 2.2; 95% CI, 1.7e2.7; P < 0.001) and those in an
LMIC (HR, 1.6; 95% CI, 1.2e2.1; P < 0.001) demonstrated a
greater risk of local treatment failure (defined as need for EBRT
or enucleation) compared with those in an HIC (Table 4C).
Multivariate analysis revealed that a higher risk was found of
local treatment failure with advanced age at presentation: age of
17.0 to 29.0 months (HR, 2.1; 95% CI, 1.6e2.6; P < 0.001) and
older than 29.0 months (HR, 2.0; 95% CI, 1.5e2.6; P < 0.001)Downloaded for Anonymous User (n/a) at University of Helsi
2021. For personal use only. No other uses without permissicompared with age at presentation of younger than 8.0 months.
In addition, a higher risk was found of local treatment failure for
unilateral retinoblastoma (HR, 2.1; 95% CI, 1.7e2.6; P < 0.001)
compared with bilateral retinoblastoma.
Discussion
A multicenter, international, internet-based registry was
used to study retinoblastoma metastasis-related mortality,
local treatment failure, and eye salvage on a global scale.
Outcomes were related to the 2017 United Nations,
Department of Economic and Social Affairs World Popu-
lation Prospects definitions of national incomes. Forty
percent of retinoblastoma patients were from HICs and 60%
were from UMICs and LMICs. This study revealed that
lower national income levels were related significantly to
increased risk of poor treatment outcomes. Specifically,
compared with patients from HICs, retinoblastoma patients747
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Figure 2. Kaplan-Meier curves showing cumulative survival estimates for all enucleated retinoblastoma patients by national income groups. HIC ¼ high-
income country; LMIC ¼ lower middle-income country; UMIC ¼ upper middle-income country.
Ophthalmology Volume 128, Number 5, May 2021from UMICs and LMICs showed a 10.3-fold risk and 9.3-
fold risk, respectively, for metastatic mortality and a 2.2-
fold risk and 1.6-fold risk, respectively, for local treatment
failure.
Table 5 compares and contrasts the Global
Retinoblastoma Study Group findings from 2017 with our
results.3 Our work showed identical demographic and
clinical features at diagnosis. Notable similarities include
the highest proportion of patients from Asia, an
association between age at diagnosis and national income
level, advanced intraocular tumor in one eye, and
increased nodal and systemic metastasis at presentation
were related to decreasing national income. Note that the
difference in geographic distribution and national income
were influenced by the heterogeneity of our LMIC group
and lack of a lower-income country group in our registry.
The greater variability in age at diagnosis and tumor stage
was found among countries in the LMIC group, which may
have affected outcomes in this category. Moreover, for
LMICs, a comparison of these two cohorts (AJCC-OOTF
and Global Retinoblastoma Study Group) suggested no
improvement in age and stage at diagnosis from 2001
through 2013 to 2017 (Table 5). Both studies emphasize the748
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Our study revealed a higher risk of systemic metastasis
and mortality on follow-up in patients with advanced age at
presentation and positive heritable trait status. These chil-
dren face a poorer prognosis because of the presence of
germline mutation, increased tumor load, risk of secondary
cancers, and often their custodian’s failure to accept bilateral
enucleation. Similarly, older children and those with uni-
lateral retinoblastoma showed a higher risk of local treat-
ment failure.
We recently published 2 validation studies of the eighth
edition of the AJCC retinoblastoma staging system that
revealed that it can be used to predict both globe salvage and
metastasis-related mortality.5,6 Together, the AJCC offers
the first uniform comprehensive classification for
retinoblastoma and a useful tool for global reporting of
treatment outcomes. Our study uniquely reports real-world
data on local treatment failure, eye salvage, and
metastasis-related mortality stratified by national income
level as well as differences in treatment outcomes from
various nations by their socioeconomic status. We showed
that children with retinoblastoma not only from LMICs butnki from ClinicalKey.com by Elsevier on December 22, 
on. Copyright ©2021. Elsevier Inc. All rights reserved.
Figure 3. Kaplan-Meier curve of cumulative proportion of salvaged retinoblastoma eyes (without need for external beam radiation therapy) by national
income groups. HIC ¼ high-income country; LMIC ¼ lower middle-income country; UMIC ¼ upper middle-income country.
Tomar et al  Global Retinoblastoma Treatment Outcomesalso from UMICs are at 9- to 10-fold higher risk of
metastasis-related death compared with those from HICs.
Poor outcomes for the world’s children affected by retino-
blastoma are related primarily to delay in diagnosis and
abandonment of treatment.38 Because of religious beliefs
and social stigma, some families refuse to accept
enucleation even for cases of unilateral retinoblastoma.
Unrealistic hope for eye salvage, particularly in advanced
cases, can result in multiple treatments and delay of local
cure and metastatic disease.10 These grave problems could
be addressed when health ministries support clinical
practice guidelines among all levels of care, led by
dedicated retinoblastoma teams, with eye cancer
specialists and skills transfer appropriate for lower-income
countries.39e42 Although early detection and prompt
enucleation are typically life saving, the relative lack of
stem-cell treatment facilities, EBRT, and salvage techniques
in lower-income countries also contribute to the disparity.
Local treatment failure and globe salvage rates follow a
similar pattern for both UMICs and LMICs. An important
reason for contrasting eye salvage has been that manyDownloaded for Anonymous User (n/a) at University of Helsi
2021. For personal use only. No other uses without permissilower-income countries lack access to advanced, end-organ
chemotherapy typically used in an HIC.3,4,43,44 Eyes with
high-risk pathologic features are at higher risk of
extraocular retinoblastoma extension and relapse. Such
cases are more frequent in developing countries, occurring
in more than 50% of children, compared with developed
countries, where they are seen in less than 20% of
enucleated eyes.45 Histopathologic analysis of enucleated
eyes from LMICs and UMICs revealed that patients with
high-risk histopathologic features (pT3 and pT4 cancers)
fared worse in comparison with HICs (see Table S3).
Our analysis found that treatment outcomes were not
statistically different between UMICs and LMICs. Howev-
er, we may not have fully captured the variability of patients
in LMICs.3 Alternatively, national income is likely not the
only metric that can be applied when gauging treatment
outcomes for retinoblastoma. Others include
socioeconomic and health-related indicators, including
annual per capita healthcare expenditure, physician and
nurse density, type of healthcare system, presence of na-
tional retinoblastoma referral centers, registries, patient749
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Table 5. Global Retinoblastoma Study Group3 Compared with American Joint Committee on CancerdOphthalmic Oncology Task
Force Retinoblastoma Study
Feature Global Retinoblastoma Study Group3
American Joint Committee on
CancerdOphthalmic Oncology Task Force
Study population 4351 patients representing
278 centers and 153 countries
2085 patients from 18 centers
and 13 countries




Geographic distribution of cases (% of patients)
Asia 52.3 48.7
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cM ¼ clinical metastasis; cN ¼ clinical node; HIC ¼ high-income country; LIC ¼ lower-income country; LMIC ¼ lower middle-income country; N/A ¼
not available; UMIC ¼ upper middle-income country.
Ophthalmology Volume 128, Number 5, May 2021gender, and religion. Such a comprehensive analysis could
provide a more nuanced picture of worldwide retinoblas-
toma and could enable treatment strategies.33 Another
interesting aspect of assessment would include studying
gender bias in disease presentation and choice of treatment
options, community impact of awareness programs,
availability of nongovernment funding for treatment and750
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Specifically, these studies should consider gender-biased
treatment options, community impact of awareness pro-
grams, availability of funding for parent counseling, and the
role of parents’ organizations.
Limitations of our study include its retrospective design
and lack of data (by design) on patient gender and ethnic andnki from ClinicalKey.com by Elsevier on December 22, 
on. Copyright ©2021. Elsevier Inc. All rights reserved.
Tomar et al  Global Retinoblastoma Treatment Outcomesracial backgrounds. It is also important to consider that
treatment strategies are evolving, and the registry data
collection was performed for 2001 through 2013. The
strengths include that this is an international, multicenter, 6-
continent, and, therefore, real-world registry-based analysis
of retinoblastoma management using a uniform staging sys-
tem across centers.
This study highlighted the persistent gap between coun-
tries for retinoblastoma stage, age at diagnosis, and treatment
outcomes. We emphasized the need to improve awareness
and detection of retinoblastoma, as well as access to treatment
in countries where resources are limited. The World Health
Organization Global Initiative for Childhood Cancer aims to
raise survival for key childhood cancers (including retino-
blastoma) to 60% by the year 2030.46 This could be feasible
through a coordinated global effort. Toward that aim,
crucial steps include: prospective collection of uniform,
multicenter, international retinoblastoma data; open-access
textbooks that allow general ophthalmologists to provide
care; and twinning programs that link higher-resource and
lower-resource centers and funded subspecialty training
programs to supply ocular oncologists for unserved and un-
derserved countries (e.g., International Council of Ophthal-Downloaded for Anonymous User (n/a) at University of Helsi
2021. For personal use only. No other uses without permissimology and The Eye Cancer Foundation - 2020
Campaign).15,47,48 With infrastructure to treat retinoblastoma
in place, government-enabled social programs can educate
parents, parent organizations, schools, and pediatricians
about early signs of retinoblastoma (i.e., leukocoria, stra-
bismus, etc.). These prerequisite measures can achieve early
diagnosis followed by prompt intervention, which has
reduced retinoblastoma morbidity and mortality effectively.
Results from both the AJCC-OOTF and the Global
Retinoblastoma Study Group suggest that advanced stage of
retinoblastoma at presentation was found to be dependent on
national income level. In addition, we found differences in
life, globe, and vision salvage in countries with lower na-
tional income. This underscores the need to improve
awareness of retinoblastoma as well as access to early
diagnosis and treatment through national and international
effort.15,49
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